证券日报网讯 2月27日，鹿得医疗发布公告称，公司2025年实现营业总收入预计为300328058.66元，同 比下降12.85%；归属于上市公司股东的净利润预计为18913373.29元，同比下降31.33%。 （文章来源：证券日报） ...

证券日报网讯 2月27日，仁度生物在互动平台回答投资者提问时表示，HBVRNA检测的关键点在于如何 在不损耗RNA的前提下排除样本中的DNA干扰。大部分患者血清中同时含有HBVDNA和RNA。RT- PCR采用的是DNA酶处理法，提取DNA+RNA两种核酸的混合物，再用DNA酶对DNA进行处理，余下 的RNA进行扩增定量，该方法会导致样本中RNA降解，进而造成检测灵敏度降低，最终引发漏检，而 且操作复杂，尚无全自动化检测系统。而公司的SAT技术可以特异提取RNA，无需DNA酶处理即可排 除DNA的干扰。该过程可实现全自动处理，精准定量HBVRNA且检测灵敏度更好。公司HBVRNA产品 用于检测血清中的乙肝RNA含量，能够更加直接反映患者肝内病毒库（cccDNA）转录活性，在疗效监 测、预测和停药评估等多个方面具有重要临床意义。 ...

Treace Medical Concepts (NasdaqGS:TMCI) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsJohn Treace - CEO, Founder, and Chairman of the BoardMark Hair - CFORichard Newitter - Managing DirectorRick Wise - Managing DirectorTripp Taylor - VP of Investor RelationsConference Call ParticipantsBen Haynor - Senior Research AnalystDanielle Antalffy - Senior AnalystRyan Zimmerman - Managing Director and Medical Technology AnalystNone - AnalystOperatorGood day. Thank you for standing by. Welcom ...

公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品牌效应，产品市场占有率持续提 升，推动了血液净化设备销售收入的稳步增长；报告期内公司自产的血液净化耗材销售收入大幅提升； 同时随着产销量的提升，自产耗材单位固定成本进一步下降，毛利率提升，公司总体盈利能力进一步加 强。 格隆汇2月27日丨山外山(688410.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入8.07亿 元，较上年同期增加42.23%；实现归属于母公司所有者的净利润1.43亿元，较上年同期增加101.89%； 实现归属于母公司所有者的扣除非经常性损益的净利润1.38亿元，较上年同期增加141.34%。 ...

2月27日的资金流向数据方面，主力资金净流出1.13万元，占总成交额0.02%，游资资金净流出215.25万 元，占总成交额2.96%，散户资金净流入216.38万元，占总成交额2.98%。 该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月27日收盘，开立医疗(300633)报收于27.09元，上涨1.35%，换手率 0.62%，成交量2.69万手，成交额7260.6万元。 近5日资金流向一览见下表： 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019 ...

报告期末，公司总资产267,401.41万元，较报告期初增长4.87%；归属于母公司的所有者权益251,585.13 万元，较报告期初增长4.95%。从过往业绩来看，公司2025年净利润高于2023年上市当年水平，但较 2024年有所回落，这也是安杰思2023年上市以来首次出现净利润同比下滑。 2月26日，安杰思（688581）披露2025年业绩快报，报告期内，公司实现营业总收入59,720.71万元，较 上年同期下降6.19%；归属于母公司所有者的净利润22,281.69万元，较上年同期下降24.06%；归属于母 公司所有者的扣除非经常性损益的净利润19,141.86万元，较上年同期下降29.81%。 | | | | ANTILI ADCID IN THE | | --- | --- | --- | --- | | 2.05 | 本报告期 | 上年限测 | And States of the comparent | | | | | (96) | | 营业总收入 | 59.720.71 | 63.663.41 | -6.19 | | 营业利润 | 26,482 33 | 34,409,27 | -23.04 ...

证券日报网讯 2月27日，佰仁医疗发布公告称，公司2025年度实现营业总收入63037.20万元，同比增长 25.60%；归属于母公司所有者的净利润20019.03万元，同比增长36.81%。 （文章来源：证券日报） ...

证券日报网讯 2月27日，天智航发布公告称，公司2025年实现营业收入28325.76万元，同比增长 58.38%；归属于母公司所有者的净利润亏损18403.18万元，亏损同比扩大51.93%。 （文章来源：证券日报） ...

证券日报网讯 2月27日，奥泰生物发布公告称，公司2025年度实现营业总收入91130.05万元，同比增长 5.16%；归属于母公司所有者的净利润为21828.01万元。 （文章来源：证券日报） ...

Core Insights - The company reported a revenue of 1.648 billion yuan for the year 2025, marking a year-on-year growth of 13.04%, with a net profit attributable to shareholders of 198 million yuan and a net profit excluding non-recurring items of 165 million yuan, driven by the deep implementation of its "integrated diagnosis and treatment" strategy [2] Group 1: Strategic Developments - In 2025, the company expanded its "integrated diagnosis and treatment" strategy, moving from the diagnostic field to treatment and from the domestic market to global markets [3] - The acquisition of Zhongshan Haiji (now known as "Sangshang Haiji") marked a key milestone in entering the health consumption sector, with plans for clinical trials for a new indication of its growth hormone injection product [3] - The company strengthened its industry influence in grassroots medical testing and upstream genetic technology through investments in various firms, enhancing its competitive edge in high-barrier segments like blood molecular diagnostics [3] Group 2: Ecosystem and Capital Initiatives - The company actively built an ecosystem of partnerships with industry leaders such as BeiGene and Alibaba Health, creating a full lifecycle service loop from screening to health management [4] - To support its integrated strategy, the company established the Hunan Jin Furong Sangshang Biological Industry Fund, focusing on AI medical applications and innovative drugs, with an initial fundraising of 820 million yuan [4] Group 3: Innovation and R&D - The company increased its R&D investment to approximately 310 million yuan, accounting for nearly 20% of its revenue, and introduced multiple innovative products in key areas such as respiratory diseases and genetic sequencing [5] - The launch of the SUREXEVO series, the world's first AI-integrated molecular POCT product, highlights the company's commitment to integrating AI across various medical applications [6] - The company achieved significant deployment of integrated machines, with over 200 units installed, and established a complete product matrix in genetic sequencing, enhancing its "instrument + reagent + data" integration [6] Group 4: Future Outlook - The chairman emphasized the need to seize the second growth opportunity in the industry by innovating new products and solutions, integrating AI deeply into all business processes, and transforming technical solutions into commercially viable products [7]